Standard BioTools switches mass cytometry buyer to Element; agreement signed, closing still pending
Summary
Standard BioTools terminated its planned sale of the Mass Cytometry Business to Multiplex Bio and signed a new definitive $5.5 million cash agreement with Element Biosystems, an acquisition vehicle formed by GMT Venture Partners. The transaction has not closed.
Source Date
September 30, 2026
Source checked
October 1, 2026
Event Type
Definitive asset-sale agreement / buyer change
Event Date
September 30, 2026
Geography
United States; global mass-cytometry customer base
Commercial Regulatory Status
Definitive sale agreement signed; NOT CLOSED. Expected by end-2026, subject to stockholder approval and other customary closing conditions.
Related CFCM Topics
Intelligence / Company Watch; Mass Cytometry; CyTOF; Hyperion; Maxpar; Spatial Biology; Single-Cell Technology
Category
Company
Primary source
Read the source →Facts supported by cited sources
Standard BioTools signed a definitive agreement on 30 September 2026 to sell its Mass Cytometry Business to Element Biosystems for $5.5 million in cash at closing. The transaction has not closed and remains subject to stockholder approval and other closing conditions.
Element was newly formed by GMT Venture Partners for the acquisition. The business includes CyTOF, Hyperion and Maxpar.
CFCM explainer — transaction status
Standard BioTools Mass Cytometry → definitive agreement with Element → closing still pending.
Source/credit: CFCM explainer based on the Standard BioTools primary release dated 30 September 2026.
For cytometry users, the practical watchpoint is continuity of instruments, reagents, software and support after closing. Statements about future investment and uninterrupted support remain forward-looking until demonstrated operationally.
Claims Requiring Caution
Why It Matters
An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →